Executive Management
Brian McNamee
|
Peter Turner |
Paul Perreault |
Gordon Naylor |
Andrew Cuthbertson
|
Jeff Davies |
Mary Sontrop
|
Karen Etchberger
|
Greg Boss
|
Edward Bailey |
Jill Lever
|
Paul Walton
|
Brian McNamee, AO
MBBS, FAICD, FTSE - (Age 54)International Pharmaceutical Industry, Medicine (Resident in Victoria)
Chief Executive Office and Managing Director
Dr McNamee was appointed to the CSL Board in July 1990 and is the Chief Executive Officer and Managing Director. Dr McNamee is a former Director of the Peter MacCallum Cancer Foundation Ltd. Dr McNamee completed Bachelor of Medicine and Bachelor of Surgery Degrees at the University of Melbourne.
Dr McNamee is a member of the Innovation and Development Committee.
Peter Turner
BSc, MBA, MAICD – (Age 62)
International Pharmaceutical Industry (Resident in Pennsylvania, USA)
Executive DirectorMr Turner was appointed to the CSL Board in December 2009. He has more than 40 years experience in the biopharmaceutical industry. His expertise includes plasma fractionation, research and development, production, engineering and management. Mr Turner contributed to the successful acquisition of Aventis Behring to form CSL Behring in 2004 served as President of CSL Behring from that time until June 2011. He was also Chief Operating Officer, CSL Group until June 2011.
Gordon Naylor
Chief Financial Officer
MBA, BEng (Hons), DipCompSc – (Age 48)
Gordon was appointed Chief Financial Officer in October 2010. He joined CSL in 1987 and has held many operational and corporate roles in different parts of the CSL Group. Prior to his current role, Gordon was based in the US and responsible for CSL Behring’s global supply chain, the supply of plasma for CSL Behring and CSL’s global information systems.
Andrew Cuthbertson
R&D Director and Chief Scientific Officer
BMedSci, MBBS, PhD – (Age 56)Andrew is responsible for CSL’s Research and Development strategy and the implementation of that strategy. He joined CSL in March 1997 as Director of Research. Andrew trained in medicine and science at the University of Melbourne, the Walter and Eliza Hall Institute, the Howard Florey Institute and the National Institutes of Health in the US. Andrew was then a Senior Scientist at Genentech, Inc. in San Francisco.
Jeff Davies
Executive Vice President, CSL Biotherapies
BSc (Hons), PhD – (Age 54)Jeff was appointed Executive Vice President of CSL Biotherapies in January 2010 and is responsible for CSL’s Australian and Asia Pacific businesses. He served as General Manager and President of CSL Bioplasma Asia Pacific from 2008 to 2010, responsible for plasma
businesses in the region. Jeff has 28 years experience at CSL including executive and senior management roles in research and development in Australia and Switzerland.
Mary Sontrop
Executive Vice President, CSL Behring Operations
BAppSc, MBA – (Age 54)
Mary was appointed as Executive Vice President, CSL Behring Operations in April 2010. She joined CSL as a Production Manager in April 1988 and has held a broad range of positions in manufacturing, quality management and general management located in Australia, Switzerland and Germany. Prior to her current position, Mary was General Manager of CSL Biotherapies for Australia and New Zealand.
Karen Etchberger
Executive Vice President, Plasma, Supply Chain and Information Technology, CSL Behring
PhD – (Age 53)Karen was appointed as Executive Vice President, Plasma, Supply Chain and Information Technology in April 2010. She joined CSL as Product Manager in JRH Biosciences in August 2001 and progressed through a number of positions in technical services, research and development, quality management, and was most recently Head of Global Quality for CSL Behring. Prior to joining CSL, Karen was Director of Developmental
Research at Endotech Corporation.
Greg Boss
CSL Group General Counsel and Executive Vice President, CSL Behring
JD, BS (Hon) – (Age 50)Greg was appointed Group General Counsel in January 2009 and is responsible for worldwide legal operations for all CSL Group companies. He joined CSL in 2001, serving as General Counsel for CSL Behring, a position he continues to hold. In addition, Greg is responsible for risk management for the Group. Prior to joining CSL, Greg was Vice President and Senior Counsel for CB Richard Ellis International.
Edward Bailey
Company Secretary and Australian General Counsel
LLB, BCom, FCIS – (Age 45)Edward was appointed as Company Secretary and Australian General Counsel in January 2009. Prior to that, he was Senior Corporate Counsel and Assistant Company Secretary, having joined CSL in 2000. Edward works with the Board to develop and maintain CSL’s corporate governance practices and provides legal advice to the Corporate Head Office and Australian operations. Prior to joining CSL, Edward was a Senior Associate with lawyers Arthur Robinson & Hedderwicks.
Jill Lever
Senior Vice President, Human Capital
BA (Hons) – (Age 55)
Jill joined CSL Limited as Senior Vice President, Human Capital in 2009. She heads the Human Resources function and works with the Managing Director and Board on strategic matters relating to talent, succession, organisation culture and executive remuneration. Originally from the UK, Jill held a number of Human Resources roles with the Royal Dutch Shell Group in Europe, the Middle East, South America and Asia Pacific before working in the finance and mining sectors in Melbourne.
Paul Walton
Senior Vice President, Corporate Development
PhD, MS, GMQ, BAppSc – (Age 54)Paul was appointed as SVP Corporate Development in January 2008. Prior to that, he was SVP Business Development at CSL Behring, and held senior roles in ZLB and JRH Biosciences, having joined CSL in 1999. Paul works with the Managing Director and the Board on corporate growth initiatives, including mergers and acquisitions. Prior to joining CSL, Paul was Vice President, Marketing, Sales and Business Development, Diagnostic Systems Laboratories, Inc., Webster, Texas.